|
GM. This is The Financial Darwin Awards, rounding up the internet's biggest Ls so you don't make them yourself. Tuesday rewarded anyone who read the specifics and punished anyone working from rules of thumb. Novartis closed down 14.14% on its third trial setback in a week. Intel rose 9.05% on the day it sold $20 billion of stock. Three people lost $72,681 between them. Each of them owned a saying instead of a situation. The traders are composites. The moves are not. Here's what we've got today:
THIS WEEK'S DAMAGE REPORT 📊
The first number is the sum of the three stories below. The second is real: Novartis closed Tuesday down 14.14%, after del-desiran missed in myotonic dystrophy, pelacarsen missed on cardiovascular risk, and eight rap-cel trials were paused following three patient deaths.
DARWIN AWARD OF THE WEEK 🏆 Every issue we crown the single worst financial decision on the internet. This week it goes to a man who mistook scale for safety. Here's the setup. u/big_pharma_is_diversified owned 1,500 Novartis shares, about $240,000, at roughly $160 each. His thesis was the one every adviser reaches for. A company that size runs dozens of programmes, so no single trial can matter much. One problem: the programmes were not independent of each other, and nor was the calendar. Del-desiran, the lead asset from the roughly $12 billion Avidity Biosciences acquisition, failed its Phase 3 study in myotonic dystrophy type 1. Pelacarsen then missed its primary endpoint on cardiovascular risk. And eight trials of the cell therapy rap-cel were paused after three patient deaths. Novartis closed Tuesday down 14.14%. That is $33,936 off a $240,000 position in one session. He was diversified across a lot of drugs. He was not diversified across one week.
Here's the thing. Diversification only works on risks that are independent of each other. That is the part worth understanding, and it cost him $33,936 to learn that a pipeline is not a portfolio.
THIS WEEK'S CASUALTIES 💀 Not everybody can be Darwin Award of the week. These two had rules of their own. Casualty #1: The Man Who Licensed It Out u/i_licensed_it_out owned 3,000 shares of Ionis Pharmaceuticals, about $174,270. Ionis discovered pelacarsen. Novartis holds the global rights under a 2019 collaboration. That arrangement is normally the attraction. Somebody else funds the trials and you keep economics on the upside. It also means somebody else runs the trial that decides whether there is any upside. When pelacarsen missed, Ionis had nothing to announce and nothing to fix. Ionis fell 9.80% in premarket trading, to $52.40. 3,000 shares, down $5.69 each, is $17,070.
Here's the thing. Licensing a drug out converts research risk into counterparty risk, without reducing the total. That is the part worth understanding, and it cost him $17,070 to learn that his upside depended on a trial he had no hand in running.
Casualty #2: The Man Who Shorted The Share Sale u/dilution_always_wins was short 2,500 Intel shares from $95.80, about $239,500 of notional. The trade is one of the most reliable patterns in equities. A company sells a large slug of new stock and the price falls to absorb the supply. Intel sold $20 billion of stock at $95 a share, upsized from a planned $15 billion. On share count alone he was right. Then the filings arrived. Nvidia had disclosed a position of roughly $30 billion. That reframes the raise. A $20 billion sale anchored by a customer and competitor is not a company scraping for cash, it is a company being underwritten by the most important buyer in its industry. DigiTimes then reported a roughly 10% processor price increase planned from October, Intel's third of 2026. Intel closed at $104.47, up $8.67, or 9.05%. 2,500 shares, against him by $8.67 each, is $21,675.
Here's the thing. An equity raise is priced on what the money buys and who is willing to fund it, not on how many shares are issued. That is the part worth understanding, and it cost him $21,675 to learn that dilution is a number and confidence is the signal.
THIS WEEK BY THE NUMBERS 📊 We track the data because the data is funnier than anything we could make up.
The S&P 500 closed down 0.58%, with healthcare the worst sector and chipmakers the best. Two of the three were on the wrong side of that split.
BITE-SIZED COPIUM FOR THE ROAD 🍪 The best part of any loss thread is the comments.
Translation: three sound rules, three situations that had not read them.
DUMB MEMES 🤣 Ours hits different when the rule of thumb was the thesis.
POV: diversified across the same fortnight
u/dilution_always_wins, finally reading the filing If you laughed, you're coping. If you didn't, go and find the saying your largest position rests on. See you next issue. Three rules. Three exceptions. Traders and P&L screenshots are satirical composites. Market data, trial results and price moves are real and dated September 8, 2026. Not financial advice. Obviously. Look at us. Stay liquid, |
Three rules of thumb met three specific situations.
Novartis fell 14.14% on its third trial setback in a week, the company that licensed it one of the failed drugs fell with it, and a man short Intel into a $20 billion share sale watched it rise 9%.
